Sunshine Biopharma Inc (SBFM)

[FeMike]

'22 Q1 quarterly fins and some research.

In '21, the total executive comp for all three was a little over $1.2 million (which is an increase of 500% over 2020, by the way). From the '21 10-k it looks like most of this shows up in SG&A.

Glancing at the '22 10-k, SG&A is up a whopping 200%. Now, I'm sure they have some other expenses, but it's a pretty close relationship. So by that, you can assume the compensation for '22 is going to be pretty close to $3million total, if not more. So $1.2 million from 2021 (12 months) plus ~$800k for Q1 this year puts you round-about that $2M over the past 15 months.